Huntington National Bank Increases Position in iShares Biotechnology ETF (NASDAQ:IBB)

Huntington National Bank raised its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 21.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,280 shares of the financial services provider’s stock after purchasing an additional 226 shares during the period. Huntington National Bank’s holdings in iShares Biotechnology ETF were worth $169,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in IBB. Nemes Rush Group LLC raised its stake in iShares Biotechnology ETF by 1,464.5% during the fourth quarter. Nemes Rush Group LLC now owns 6,430 shares of the financial services provider’s stock valued at $850,000 after buying an additional 6,019 shares during the last quarter. Hoey Investments Inc. purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter worth about $70,000. Edmond DE Rothschild Holding S.A. grew its position in iShares Biotechnology ETF by 636.3% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 5,890 shares of the financial services provider’s stock valued at $779,000 after purchasing an additional 5,090 shares during the last quarter. O Shaughnessy Asset Management LLC increased its stake in iShares Biotechnology ETF by 10.8% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 2,745 shares of the financial services provider’s stock valued at $363,000 after purchasing an additional 267 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in iShares Biotechnology ETF by 2.8% in the fourth quarter. CIBC Private Wealth Group LLC now owns 13,628 shares of the financial services provider’s stock worth $1,837,000 after buying an additional 375 shares during the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Down 5.4 %

NASDAQ:IBB opened at $117.16 on Friday. The stock has a market cap of $5.27 billion, a price-to-earnings ratio of 24.21 and a beta of 0.82. The company’s 50 day moving average price is $134.95 and its 200-day moving average price is $138.11. iShares Biotechnology ETF has a 52 week low of $117.02 and a 52 week high of $150.57.

iShares Biotechnology ETF Increases Dividend

The firm also recently announced a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were paid a dividend of $0.1212 per share. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.